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Chapter 1
Introduction
In December 2011, the World Health Organization released a report estimating the 
number of worldwide HIV/AIDS cases at 30 million.1 HIV/AIDS is an antiretroviral disease that
affects the immune system by destroying cells vital to the body’s immune response. This is 
accomplished by two general mechanisms: killing the host cells, and killing uninfected 
neighboring cells. Both mechanisms are based on manipulation of the genetic information 
contained within ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) of a type of immune
2cell called the CD4+ cell.
In the early stages of HIV infection, the virus takes over the RNA replication mechanism 
of CD4+ cells and begins to replicate. When infected RNA is used as a blueprint to manufacture 
DNA, the HIV virus’s genetic information is inserted into the cell’s DNA. This infected DNA is
then used as a blueprint for more HIV viruses, and molecules that induce cell death, or apoptosis,
called cytokines. The infected cell dies, releasing the HIV and cytokines into the blood stream. 
While the HIV virus attaches to neighboring cells, the cytokines attach to receptors on uninfected 
cells and induce apoptosis. As the virus continues to replicate, the CD4+ cells die. When a 
person’s CD4+ cell count drops from the normal level of 1000/mm3 to below 200/mm3 of blood,
the patient has progressed to the AIDS stage of the disease. After the disease progresses to AIDS, 
the patient’s immune system is severely compromised. Most people are aware of the disease’s
effects on the immune system, but few realize the impact that HIV/AIDS has on the auditory
system.
In 1998, Moazzez and Alvi reported that anywhere from 20-50% of HIV/AIDS patients
experience some degree of sensorineural hearing loss. These hearing losses can result from viral
2
attacks on the auditory nerve, as a byproduct of complications from opportunistic infections that 
attack the central nervous system，or as a side effect of ototoxic drugs, which affect the cochlea 
and/or auditory nervous system.4 Instances of hearing loss in HIV patients are well documented. 
Marra et al. found that 29% of the patients in their 1997 study on the prevalence of hearing loss 
in HIV patients taking antiretroviral drugs had hearing loss, defined as a hearing threshold 
>25dBHL at 4000Hz.5 Another study performed by McNaughten, Wan, and Dworkin in 2001 
determined the prevalence of hearing loss among HIV-infected patients by examining data from
the Adult Spectrum of HIV Disease (ASD) project. Of the 3646 patients enrolled in the ASD，30
were identified as having a hearing loss with unspecified thresholds. This low prevalence was
attributed to the practice of retroactively examining medical records. The investigators believe 
that the prevalence of hearing loss would increase if there were audiometry results on file for
6each patient.
HIV patients experience both conductive and sensorineural hearing losses. Most
conductive losses are caused by opportunistic infections. Some of the most common ear
pathologies in HIV patients include otitis media, nasopharyngeal polyps, mastoiditis, and otitis 
externa associated with Kaposi’s sarcoma or herpes zoster.7 When Chao et al. conducted a study
on the prevalence of hearing loss in HIV-positive children in Peru in 2011，they found that
34.5% of the subjects had a conductive hearing loss. Ninety-eight percent of these children were
receiving highly active antiretroviral therapy (HAART), and a large number of the children
presented with middle ear pathologies, including otitis media and abnormal tympanograms. The
prevalence of hearing impairment in the HIV-positive children was five times higher than the
8prevalence of hearing impairment in HIV-negative children.
3
While it is fairly simple to identify the cause of a conductive hearing loss, identifying 
sensorineural hearing losses and their causes is much harder. In 2008, Ranjan and Bhat compared 
the distortion product ototacoustic emissions (DPOAE) of HIV-positive individuals to those of 
HIV-negative individuals. Fifty percent of the HIV-positive patients in the experimental group 
demonstrated DPOAE readings that indicated subclinical sensorineural hearing loss. Because 
these losses occurred at frequencies higher than 1000Hz, it is possible that the affected patients 
had not yet noticed them. In this study, the researchers did not explore the cause of the abnormal
9DPOAE readings.
While there are many accepted causes of sensorineural hearing loss, such as noise 
exposure, and neuropathy, one of the most intriguing possible factors in patients with HIV is 
ototoxicity. In 1997, the World Health Organization published a report that defined ototoxicity as
any damage caused to the organs of hearing and balance by drugs. The report goes on to state 
that cochlear ototoxicity tends to present as tinnitus, followed by a high frequency hearing loss. 
The patient might not notice these losses until they reach a threshold of >30dBHL. 10 Some
investigators postulate that a common class of antiretroviral drugs called nucleoside reverse
transcriptase inhibitors (NRTIs) maybe responsible for sensorineural hearing loss caused by
ototoxicity. NRTIs inhibit HIV’s replication process by competing with the virus for the
attention of reverse transcriptase enzymes. Once the NRTIs are incorporated into the cell DNA,
they send signals that shut down the transcription mechanisms. While this stops HIV from using
the cell to replicate itself, it also stops the production of the enzyme responsible for basic cell
iifunctions.
One type of cell organelle affected by this shut down is the mitochondrion. The
interruption in enzyme production affects the mitochondria’s ability to synthesize mitochondrial
4
DNA (mtDNA). Mitochondria are organelles responsible for energy production. If the 
mitochondria are unable to correctly produce the energy molecule adenosine triphosphate (ATP), 
the cell might not receive enough ATP to function correctly.13 Henderson et al. (2006) reports 
that it is possible that metabolic stress due to insufficient energy production can case damage to 
cochlear hair cells.14 While the exact cause of mitochondrial disease is difficult to determine,
there is significant evidence of involvement of the cochlea. Mitochondrial deafness is almost 
always sensorineural, progressive, and symmetrical. It occurs at high frequencies, and is often
13exacerbated by noise exposure.
The combination of the above factors, especially the possible relationship between
sensorineural hearing loss and NRTI use, has led several scientists to begin research on the 
ototoxicity ofNRTIs. Our limited ability to pinpoint the cause of mitochondrial deafness has led
to speculation of contributing factors that increase the likelihood of sensorineural hearing loss in
patients receiving HAART.
This systematic review will examine studies concerned with the ototoxicity of four
antiretrovirals administered to HIV-positive patients: 1) didanosine, 2) stavudine, 3) lamivudine,
and 4) zidovudine. While other antiretrovirals have been associated with ototoxicity, these four
drugs are still commonly used in HAART. The following studies examine several scenarios
involving ototoxicity alone, and ototoxicity in conjunction with age and/or noise exposure in
order to investigate the possibility of ototoxicity associated with NRTI use.
5
Chapter 2
Review of the Literature
Method
Due to the limited amount of available research, subject selection criteria for this review
were broad. This review included both human and animal studies. Human studies consisted of
individual case studies and group studies. While preference was given to experimental studies, 
the inclusion of case studies was necessary due to the paucity of research in this area. The
number of participating subjects ranged from 1 to 99. Age, ethnicity, and geographic location
were not restricted.
Restricted criteria included study publication date and drug type. Studies published
before 1995 were excluded from this study because most NRTIs were approved for use in or
before that year. Research prior to 1995 focused on drug development and the most pressing side
effects, while current research has focused more on quality of life issues. Drug type was
restricted to ensure that studies focused on the most commonly administered NRTIs: didanosine, 
lamivudine, stavudine, and zidovudine. While there have been cases of permanent hearing loss 
associated with the ototoxic effects of the NRTI zalcitabine,15 studies on the effects of
zalcitabine were not included in this review because of the recent decline in zalcitabine
prescriptions. The complexity of drug regimens rendered it necessary to include studies that 
accepted patients with a multi-drug therapy regimen; as a result, many of the patients detailed in
the following studies were not taking the aforementioned drugs exclusively.
In order to obtain the most relevant research, database was not restricted. Searches were
performed within the Medline and ComDisDome databases, but did not yield relevant results.
6
Most studies were selected after extensive hand searching. The primary source used in
collecting the reviewed studies was the book HIV/AIDS Related Communication Disorders,
which was compiled in 2010 by De Wet Swanepoel and Brenda Louw. Background and 
supporting information was obtained by hand searching the references used in the reviewed
studies. Initial searches yielded about fifty articles, but ultimately, only eight articles met the
aforementioned criteria.
While the initial purpose of this review was to examine the effects ofNRTI use on
hearing, it is impossible to ignore the affects of complex physiological and chemical interactions. 
Asa result，several investigators took a holistic approach when researching the ototoxic effects
ofNRTIs. Based on the information obtained during the research process, included studies are
divided into two categories: hearing loss caused by ototoxicity alone, and ototoxicity
concomitant with other factors.
7
Results
Toxicity
The first two studies in this review concern children bom to HIV-positive mothers.
Children of HIV-positive mothers are usually exposed to antiretrovirals in one of two ways. One 
way is an HIV-positive woman may take antiretrovirals before she is aware of the pregnancy. 
The second common method of exposure occurs when doctors administer prophylactic doses of 
antiretrovirals to a pregnant mother in order to reduce the risk of virus transmission during 
childbirth, or the development of the disease in early childhood. Occasionally, these prophylactic
treatments will be administered directly to the child postnatally. While there is no dispute over
the effectiveness of these treatments, there are concerns about the potential side effects when
these drugs are administered to infants and young children.
led Poblano, Figueroa, Figueroa-Damien, and Schnass to examine the effect 
of prenatal exposure to zidovudine and lamivudine on brainstem auditory evoked potentials 
(BAEP). Subject selection for this study was complicated because the investigators had to find 
mother/infant pairs where both individuals met all inclusion criteria. Only mothers with low-risk
This concern
pregnancies and generally healthy infants were included in the control and experimental groups.
The investigators identified thirty-seven suitable mother/infant pairs. The assembled control 
group consisted of thirty-seven full-term infants selected based on head circumference.16 This 
choice was justified by the results of a study by Rothenberg, Poblano, and Schnass, in which the
17authors reported cephalic perimeter to be a covariant of BAEP.
Twelve of the infants in the experimental group were exposed to only zidovudine, while
the other fifteen infants were exposed to a combination of zidovudine and lamivudine. All
measurements were made in the neonatal period, and fell within the expected laboratory ranges
8
for BAEP measurements. While none of the measurements were outside of expected range, the 
investigators noted a statistically significant increase in the latency of the I-III waveforms of the 
exposed infants, compared to those of the control group. The type of drug therapy each exposed 
infant received was not significantly related to the BAEP readings of the exposed infant. Poblano 
et al_ concluded that prenatal exposure to antiretroviral drugs subclinically affected the 
development of auditory regions in the brainstem. At the end of the study, none of the infants 
exposed to antiretrovirals demonstrated a clinical hearing loss, but the long-term effects of these 
subclinical developmental abnormalities remain unknown.
The strengths of this study include careful subject selection and blinding of results. The 
scientists responsible for administering the BAEP tests did not know the exposure status of the 
infants. This practive prevented bias in interpreting the results of each infant’s BAEP test. The 
investigators found no statistically significant differences between the experimental group and 
control group in gestational age, Apgar score, and age of BAEP testing. The similarity of infants
16
in both groups eliminates confounding variables and lends credibility to the results. Blinding the
results of the BAEP testing further strengthens the study.
Despite these strengths, there were weak points in the study. Poblano et al. acknowledged
that the small sample size and short follow-up period prevented the formulation of a strong
conclusion. They suggested that subsequent studies should obtain more subjects and follow
subjects longer postnatally to examine potential effects of the subclinical differences in the
auditory pathway. Another aspect of this study that can be improved is the way the investigators
monitor prenatal levels of antiretrovirals. Determining the degree of exposure needed to produce
subclinical abnormalities would have strengthened the study.
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While the previous study followed infants with prenatal exposure to antiretrovirals, it is 
also important to examine the effects antiretrovirals might have on young children taking the 
drugs. Christensen et al. published a case study that followed a young girl from birth to 43 
months of age.18 The subject’s mother was HIV-positive, but there is no information about 
possible prenatal exposure to antiretrovirals. The subject was prescribed the prophylactic 
bactrim, but her parents reported inconsistent administration. At one year of age, the subject was 
classified as HIV-positive with decreased immune function and no significant audiologic history. 
The subject was placed on zidovudine and didanosine in December 1995 at two years of age.
The subject’s adherence to the treatment regimen was sporadic until the subject moved in with
her grandmother in fall 1996.
The subject’s first evaluation occurred when she was 21 months old, during the period of 
intermittent treatment adherence. The subject did not tolerate earphones and could not be
conditioned for play audiometry, so the investigators used visual reinforcement audiometry 
(VRA) to measure behavior response thresholds. The thresholds were measured within normal
limits. The child was sedated during testing of transient otoacoustic emissions (OAEs). OAEs
were present at 800-4000 Hz, with a response level of 18.8 dB in the left ear, and 21.1 dB in the
right ear.
When the subject was evaluated at 34 months, her grandmother reported consistent use of
zidovudine and didanosine. The subject continued to resist play audiometry conditioning and
refuse headphones. Only ABR testing was performed due to time constraints. The subject’s wave
V latencies showed a significant decrease from the first evaluation, indicating a developing high
frequency hearing loss.
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In the third evaluation, performed at 43 months, the child had continued regular use of 
didanosine and zidovudine, but showed signs of possible viral progression. This could indicate 
that the antiretroviral therapy was no longer effective. The subject continued to refuse 
headphones and resist conditioning. VRA detected a hearing loss at 4 kHz with a threshold of 
40dB. The researchers were unable to obtain OAEs due to lack of cooperation from the subject.
Auditory brainstem response (ABR) testing showed that wave V latency continued to decrease. 
ABR was normal at .5 kHz, but showed no response at 8.5 kHz up to a threshold of 45 dB. There 
a robust response at 75 dB. The subject awoke before an exact threshold could be 
determined, but a normal tympanogram indicated that the subject’s high frequency hearing loss
was
18was sensorineural.
This study is unique in that the investigators were able to follow the child from initiation 
of antiretroviral therapy, providing a thorough look at the deterioration of the child’s hearing.
Although the investigators were unable to use pure tone audiometry, the results can be
considered reliable due to the consistent use of ABR at each testing session. In the future, it
would be preferable to obtain a pure-tone audiogram so that the child is unable to rely on the use
of the good ear during testing.
While the previous studies investigated the effects of young children exposed to HIV,
Rey et al examined ototoxicity in a previously healthy young woman exposed to antiretrovirals.
18 They reported on a case of severe ototoxicity in a 23-year-old female medical student. The
medical student was exposed to HIV while working on a patient with poor adherence to a highly
active antiretroviral (HAART) routine. The student was given a prophylactic treatment of
stavudine, lamivudine, and nevirapine. Less than two weeks after conclusion of treatment, the
subject reported a sudden bilateral hearing loss with associated dizziness and tinnitus.
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The student was examined, and an audiogram showed that the subject had a bilateral 
sensorineural hearing loss, predominantly between 2 and 4 kHz. The subject’s CT and MRI were 
normal. An ABR test showed a moderately decreased left latency for wave V. The student was 
treated with the steroid prednisolone for ten days, but showed no change. Several months after 
the initial prophylactic treatment, there was a slight improvement when the student received 
treatment with clonazepam and vestibular reeducation sessions. The student remained negative 
for HIV. Neuroradiological and otological examinations revealed neurologic damage to the inner 
After ruling out any other factors, the investigators concluded that stavudine was the likelyears.
19cause of the student’s hearing loss.
The strength of this case study is the health of the subject. The typical antiretroviral 
patient has a severely compromised immune system. Even if an HIV patient is considered 
relatively healthy, the body’s defenses are still impaired. The medical student in this case study 
reported no serious illnesses that would act as confounding variables. Furthermore, due to the 
sensitivity of the situation, the student’s progress was closely monitored from the time of
exposure. This ensured that any change in the student’s status would be noted and documented,
which provided the investigators with a comprehensive view of the nature of the toxicity.
The subjects in the previous studies appear to have irreversible effects from the ototoxic
effects of antiretrovirals. In a case study by Colebunders, Depraetere, Wanzeele, and van
20Gehuchten, the subject’s hearing returned to normal levels after discontinuation of the drug.
The subject was a 37-year-old, homosexual Belgian man who began treatment with
zidovudine in 1990. Zidovudine was replaced with didanosine in 1992. The subject was
hospitalized with an infection in February 1996 and antibiotics were administered. In May 1996, 
the subject developed bilateral deafoess. Tests showed normal bilateral otoscopy and normal
12
tympanometry. There was evidence of 40-60 dBhl bilateral sensorineural hearing loss. ABR
testing showed increased bilateral latency of wave V，and an increased I-V interval. Didanosine
20was discontinued and audition returned to normal in August 1996.
Despite the seemingly dramatic results, this study is severely limited. The report did not 
include a complete case history. The investigators used appropriate tests to assess the subject’s 
condition, but, as the subject was never re-challenged with didanosine, the exact cause of the
subject’s sudden hearing loss remains unclear.
Toxicity Concomitant with Age and/or Noise Exposure
In 2008, Bektas, Martin, Stagner, and Lonsbury-Martin used DPOAE and auditory 
brainstem response (ABR) testing to measure the function of outer hair cells in mice treated with
The experimental group consisted of ten, eight-21a combination of zidovudine and lamivudine.
week-old female mice from the same commercial strain. Ten mice of the same age and strain
made up the control group. The mice were given a combination of zidovudine and lamivudine 
orally by dissolving the drugs in drinking water. In phase 1，the experimental group received a 
twelve-week course of antiretroviral therapy, and DPOAE and ABR testing was performed
weekly. After twelve weeks of drug administration and testing, the investigators concluded that t 
1) there was no significant difference in hearing levels between the two groups of mice at the
beginning of the study, and 2) the mice receiving the antiretrovirals showed no measurable
change in DPOAE results.
In the second phase of this experiment, the mice were maintained on the drug regimen for
one week, and then exposed to a 10kHz octave-band noise. DPOAE results were collected
immediately after noise exposure, two days after exposure, and two weeks after exposure.
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Immediately following noise exposure, the both groups presented with reduced measurements of
DPOAEs at all levels. By the second day post-exposure, both groups of mice showed similar
substantial recovery of DPOAE responses. After two weeks, however, the experimental group 
continued to exhibit high frequency hearing loss, while the control group showed DPOAE levels
21consistent with baseline magnitudes.
While the investigators in this study conducted a well-documented and controlled study, 
the experiment had several limitations. First, the sample size was relatively small. While caring 
for more mice would require more labor and funding, a larger sample size would increase the 
validity of the study. Another shortcoming of this study is the lack of blinding. Blinding the drug 
administration and testing scenarios would greatly increase the level of evidence this study
provides.
Although the research done by Bektas et al. was performed on mice, the findings of that 
study are consistent with the findings of a study Simdon, Watters, Bartlett, and Connick 
conducted on humans in 2001.22 Simdon et al. examined the cases of three HIV-1 positive men
treated at an infectious disease clinic at the Denver Veteran Affairs Medical Center (DVAMC)
between 1997 and 2000. All of the subjects had a history of noise-induced hearing loss from 
occupational noise exposure, and no history of opportunistic infections or family history of
hearing loss.
The first subject in the study is a 53-year-old male diagnosed with HIV in 1987. The
subject was on zidovudine monoptherapy from 1988-1996. The subject complained of tinnitus in
1991, and a noticeable decline in speech discrimination in 1993. Medical records from 1986-
1996 revealed a progression from a mild to severe high frequency hearing loss. In December 
1996, the subject’s drug regimen was changed to didanosine, stavudine, and nevirapine. Hearing
14
tests showed a continued decline in hearing acuity through June 1997. At the end of the study,
the subject reported that his profound hearing loss interfered with his ability to socialize.
Subject two was a 47-year-old male who first presented to the DVAMC in 1992. The 
subject had a history of a stable，mild hearing loss, and tinnitus since 1966. In 1996, the subject 
began a drug regimen that included indinavir, stavudine, and lamivudine. Though the subject 
showed improvement after two months, indinavir was removed from the ART regimen due to 
side effects. The subject continued to use stavudine, lamivudine, and various protease inhibitors 
for two years. After the subject reported hearing deterioration in 1997, testing revealed 
moderately severe bilateral hearing loss substantially greater than the results of the subject’s last
hearing examination in 1985.
The subject’s ART regimen was changed again in September 1998 to include didanosine, 
stavudine, lamivudine, and other drugs. In January 1999, the subject reported peripheral
neuropathy and severe tinnitus. His ART regimen was discontinued, and the peripheral
neuropathy and tinnitus improved. When the subject was returned to a didanosine-free ART
regimen in April 1999, the neuropathy and tinnitus returned in full force. In December 1999,
testing revealed a severe hearing loss. Upon conclusion of the study, the subject wore bilateral
hearing aids and reported intolerable tinnitus.
The final subject in this study was a 43-year-old male with a history of HIV for at least
fourteen years. He first presented to the DVAMC in October 1998 as a treatment-naiVe patient.
The subject had a history of stable hearing loss in the left ear since the early 1970s. Initial ART
included stavudine and lamivudine. Four months after beginning the new drug therapy, the
subject reported tinnitus and a noticeable decrease in hearing acuity. Over the course of two
months, the subject’s hearing loss worsened, and his tinnitus progressed from intermittent to
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consistent. One month after the subject’s physician replaced stavudine with zidovudine, the 
subject reported some improvement of the hearing loss and tinnitus. Subsequent testing revealed 
a mild hearing loss in the right ear, and a moderately severe hearing loss in the left ear. These 
losses were unchanged during a two-month period, and continued to persist throughout the end
22of the study.
This study is problematic for several reasons. First, it consists entirely of case studies. 
The limited number of subjects makes it hard to generalize the results. The level of evidence is
lowered further by the lack of experimental data. The investigators did not have the ability to 
prescribe a uniform ART regimen to the subjects, or any method to control for preexisting noise 
exposure or hearing loss. Strengths of this study include the relatively similar age and 
occupations of the subjects, and the extensive medical histories provided by the DVAMC.
Another possible concomitant factor with ototoxicity is age. In 1997, Marra et al.
performed a case control study to investigate the association between antiretrovirals and hearing 
loss in HIV-positive patients.5 The study enrolled 99 HIV seropositive volunteers to undergo
standardized interviews, medication reviews, and hearing tests. The same investigator was
responsible for conducting all tests and interviews. Hearing tests consisted of air conduction
screening，and all subjects with thresholds >25dB at 4 kHz in at least one ear were determined to
have hearing loss. Using this method, 46 subjects were diagnosed with hearing loss. The
investigators then analyzed the collected data and found a statistically significant association
5between hearing loss and antiretroviral use in subjects 35 and older.
The main concern in this study is the complete lack of blinding. There is an increased risk
of bias due to the fact that the same investigator conducted the medical history interviews,
medication reviews, and hearing screenings. The study would be strengthened if a different
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investigator administered each test. Another issue with this study is the wide variety of 
antiretroviral therapies administered to subjects. The only therapy-related selection criteria 
required subjects to have filled a prescription for any drug classified as ototoxic within six 
months. Even though Marra et al. thoroughly analyzed the collected data, the lack of continuity 
in treatment regimen severely limits interpretation of these results.
Schouten et al. conducted the only study in this review that did not find a relationship 
between NRTIs and ototoxicity.23 The investigators conducted a prospective observational pilot 
study on a group of thirty-three antiretroviral naive subjects being treated with didanosine and 
zidovudine. Exclusion criteria included hearing loss requiring hearing aids, and substance abuse.
Subjects underwent audiometric testing prior to initiation of the study, and at 16 and 32 
weeks into the study. At each visit, the investigators measured the subjects’ viral load, performed
tympanometry, and air conduction screening. Bone conduction testing was performed as needed. 
At the first visit, the investigators established a baseline that was used to evaluate hearing levels
at subsequent visits.
At the beginning of the study, twenty-two subjects had a hearing level greater than 25 dB
at one or more frequencies, sixteen subjects had a hearing level greater than 40 dB (primarily at
high frequencies), and seven subjects had a hearing level greater than 60 dB (again, primarily at
high frequencies). Although most of these increased hearing thresholds occurred primarily at
high frequencies, only 16 subjects reported a history of sound exposure, and 14 reported tinnitus.
Subject attendance at the 16- and 32-week follow up visits was sporadic, but those who
reported for testing demonstrated a trend of improvement from baseline measurements. At the
end of the study, the investigators found that regardless of age, history of noise exposure, or
17
baseline viral load, there were no statistically significant changes in hearing over the course of
23the study.
As one of the only prospective studies available on this subject, the present study
demonstrates a higher level of evidence than the case studies in this review. While most of the
case studies receive a grade of 3 on the Oxford scale of evidence, this study is a randomized 
controlled study, and receives a grade of lb. 24 The use of treatment-naive patients and detailed 
audiometry lends credibility to the study, but there are several areas of concern. The small
sample size, coupled with the lack of a control group makes generalization of the results
particularly difficult. Furthermore, this small sample excluded subjects with a pre-existing
hearing loss requiring hearing aids. This is problematic because of previous findings that subjects
with a greater degree of pre-existing hearing loss are particularly susceptible to hearing loss
when treated with NRTIs. The investigators were also unable to randomize the treatment
regimens of study participants. Finally, the timeline for follow-up visits in this study was very
short. If there are no detrimental side effects, the subjects of the study may stay on the prescribed
drug regimens for months or years. The fact that this study was finished in less than a year leaves
unanswered questions about the long-term side effects of didanosine and zidovudine.
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Level of Evidence
As shown in the chart below, the overall level of evidence of the studies in this review is 
quite low; most of the studies only have a level of evidence grade of 3.24 Although the original
intent of this review was to obtain a higher overall level of evidence, only eight studies met the
inclusion criteria. The qualifying studies had a tendency toward being descriptive, rather than
experimental.
2424Type of Study 
Randomized controlled study
Case study 
Case study 
Case control 
Controlled study without 
randomization 
Case study
Non-experimental study 
Case Series
Level of Evidence! Study (by author) 
Bektas 
Christensen 
Colebunders19 
Marra 
Poblano
20 lb
17 3
3
5 3
16 2b
18 3Rey
22 3Schouten
Simdon21 3
16,21 there is an overall lack ofWhile some of the studies utilized control groups,
blinding. In order to increase the level of evidence surrounding this topic, an effort should be
made to design more blinded, experimental studies. While ethical constraints might prevent most
researchers from conducting clinical trials, or randomized human studies, it is still possible to
blind certain aspects of the studies. In the 2008 Bektas study, the investigators could have
blinded the administration of antiretrovirals by housing all of the mice separately, rather than just 
the mice receiving antiretrovirals. In human studies like the one conducted by Marra et al. in
1997, it is possible to blind results by using different investigators to conduct subject interviews
and audiometric testing. These tasks can also be outsourced to qualified professionals not
otherwise involved in the study.
19
Chapter 3
Discussion
Although the lack of randomized, controlled studies that qualified for this review was
originally disappointing, it was not surprising. The low number of available studies indicates that 
research on the ototoxicity of NRTIs is still in the early stages. Although research will continue
to progress, it is unlikely that the average study on the ototoxic effects of antiretroviral drugs will 
be a randomized, controlled trial. Aside from the ethical concerns of randomizing the distribution
of drugs to critically ill patients, there are several obstacles that prevent investigators from
determining the exact ototoxic effects of antiretroviral drugs.
First and foremost of these obstacles is the complexity of the ART regimens. The United
States Food and Drug Administration (FDA) has approved twenty-three single drugs from six 
different drug classes for the treatment of HIV-positive patients. The FDA has also approved the 
use of eight fixed-dose combination drugs, which include drugs from two or more classes in one 
dose. 25 In the United States, ART regimens are normally decided upon after careful 
consideration of the patient’s history, current medication the patient is taking, and side effects of 
the ART medication. Most of these regimens include two or three antiretrovirals, complicating
26researchers* ability to determine the cause of hearing loss.
These complex drug interactions are further complicated by the tendency of HIV patients
to require extensive medical care, due to their weakened immune systems. HIV patients are
highly susceptible to opportunistic infections that must be treated with ototoxic antibiotics. For
example, aminoglycosides are commonly prescribed to treat diseases such as tuberculosis, and 
are a known toxin for the hair cells in the inner ear. It is postulated that interactions between
two ototoxic drugs may increase the likelihood of hearing loss. This problem is of particular
20
concern in countries like South Africa, where patients receiving high-dose antiretroviral 
medications are exposed to highly infectious diseases like tuberculosis. 28 This example shows 
that while the complexity of drug regimens must be accounted for, study design is also affected
by demographics.
While the mechanism of HIV/AIDS infection is the same across the globe, there are
distinct differences in the affected populations of different countries. For example, a 2008 WHO 
report estimated that in Swaziland, between 20% and 37% of young adults aged 15-24 years are 
infected with HIV/AIDS, and the adult HIV rate was estimated to be about 26%. 29 In the United
States, less than 2% of young adults age 15-24 were living with HIV/AIDS in 2008, while the 
adult infection rate was only 0.6%.30 Age is an important demographic factor because older HIV
5patients are more likely to have a history of hearing loss.
Other demographic considerations include income, access to healthcare, and availability
of treatment. The aforementioned WHO reports show large disparities between the United States
and Swaziland in all three of these categories. These gaps are consistently present in
comparisons of a developed nation to a developing nation. While American HIV patients have 
access to complex drug regimens and advanced audiological services, most African patients are 
prescribed high doses of low-cost drugs, like zidovudine, with little to no monitoring. In 2009,
Fagan and Jacobs conducted a survey of the availability of otolaryngology, audiology, and
speech therapy services in eighteen Sub-Saharan countries, compared to the availability of the
same services in the United Kingdom. The investigators found that all of the African nations
reported poor access to the most basic audiologic services, including screening and hearing aids. 
If studies are conducted in developing countries, the lack of audiology facilities might result in31
28trouble obtaining high frequency audiometric data, and sporadic subject attendance.
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Regardless of these barriers, it is important that research on the ototoxicity of
antiretrovirals continues to advance. As treatment regimens become more effective, HIV patients 
are living longer, but are beginning to suffer from side effects of their medication. This change in
the needs of HIV patients allows researchers to shift their focus from merely keeping patients 
alive to improving quality of life. The studies reviewed in this report suggest two areas of
concern that scientists should continue to investigate.
The possible correlation between age, noise exposure, and hearing loss in patients treated 
with NRTIs is especially relevant in highly industrialized countries, where HIV patients are more 
likely to survive to old age. Research in these countries might include identification of at-risk 
populations, and investigation into more effective hearing protection protocols. For example, 
members of the U.S. military who have been exposed to HIV are also likely to have a history of 
noise exposure. These patients should be counseled on ways to protect their hearing during their 
term of service, and after return to civilian life. Further research into the relationship between
NRTI ototoxicity and concomitant factors will increase scientific knowledge that can be used for
awareness campaigns and patient education.
Prenatal exposure to potentially ototoxic NRTI regimens is another area of concern.
While transmission of HIV from mother to child is a global problem, children bom in developed
countries are less likely to contract the virus, and therefore are exposed to fewer antiretrovirals.
Meanwhile, developing countries have a much higher incidence of childhood HIV infection. It is 
important for researchers in these countries to examine the long-term effects of NRTI exposure
on a child’s auditory system.
While regional differences in populations affected by the disease complicate efforts to
conduct research on NRTI ototoxicity, they also encourage global collaboration. The above
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suggestions of regional research interests are by no means exclusive. Children in the USA are
just as susceptible to hearing damage as children in Chile or Botswana. Likewise, adults in
developing countries may work around noisy machinery while taking NRTIs. If researchers 
continue to conduct ototoxicity research relevant to the unique HIV-positive populations of their
home countries, the knowledge gained through these endeavors maybe applied to other HIV­
positive populations. Global collaboration will be essential not only in determining the risk 
NRTIs pose to hearing, but in addressing, and eventually solving, the potential auditory side
effects faced by millions of HIV patients worldwide.
Currently, one has to conclude that the evidence that NRTIs affect hearing is
inconclusive. Most hearing losses that have been associated with NRTI use are characterized as
high frequency sensorineural losses. While there have been reports of concomitant factors like
age and noise exposure increasing the likelihood of hearing loss in patients, there has been no
definitive information to explain the cause of these losses. Further research is needed to
determine the full effects of NRTIs on hearing and the auditory system.
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